Talzenna approved by FDA: FDA Approves... - Prostate Cancer N...

Prostate Cancer Network

5,258 members3,325 posts

Talzenna approved by FDA

Magnus1964 profile image
3 Replies

FDA Approves Talzenna for Metastatic, Castration-Resistant Prostate Cancer

Significant radiographic progression-free survival seen for homologous recombination repair gene mutation, including with BRCA mutation

HealthDay

MONDAY, June 26, 2023 (HealthDay News) -- The U.S. Food and Drug Administration has approved Talzenna (talazoparib) with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).

The approval was based on a trial in which 399 patients with HRR gene-mutated mCRPC were randomly assigned (1:1) to receive enzalutamide 160 mg daily plus either talazoparib 0.5 mg or placebo daily.

The results of the trial showed statistically significant improvement in radiographic progression-free survival (rPFS) for Talzenna with enzalutamide versus placebo. Median rPFS was not reached in the Talzenna group versus 13.8 months with placebo (hazard ratio, 0.45; 95 percent confidence interval, 0.33 to 0.61; P < 0.0001). For 155 patients with BRCA-mutated mCRPC, the hazard ratio for rPFS was 0.20 (95 percent confidence interval, 0.11 to 0.36), but for HRR gene-mutated mCRPC without BRCA mutations, the hazard ratio was 0.72 (95 percent confidence interval, 0.49 to 1.07).

Recommended dosing is 0.5 mg orally once daily for Talzenna in combination with enzalutamide (160 mg orally daily) until disease progression or unacceptable toxicity. Patients receiving this combination should also receive a gonadotropin-releasing hormone analog concurrently or should have had bilateral orchiectomy.

The most common adverse reactions (≥10 percent) included decreased hemoglobin, neutrophils, lymphocytes, platelets, calcium, sodium, phosphate, magnesium, and potassium, as well as nausea, decreased appetite, fractures, dizziness, increased bilirubin, and dysgeusia. A blood transfusion was needed among 39 percent of patients treated with Talzenna with enzalutamide, including 22 percent who required multiple transfusions.

Approval of Talzenna was granted to Pfizer.

Written by
Magnus1964 profile image
Magnus1964
To view profiles and participate in discussions please or .
Read more about...
3 Replies
Mw921000000 profile image
Mw921000000

Do we know if Talzenna can be used if xtandi resistance has already occurred?

Magnus1964 profile image
Magnus1964

I am reading you question right, I don't think Talzenna is a re-sensitizing agent for Xtandi or any ADT drug

pretty harsh SEs

Not what you're looking for?

You may also like...

FDA approves Erleada for metastatic hormone-sensitive prostate cancer

Joining Zytiga, and docetaxel. Probably Xtandi too very soon....
Tall_Allen profile image

PSA not covered by Medicare

Is it true Medicare only pays for one PSA per year? This is my first year, getting PSA every 3...
Muggs1 profile image

Confused by 2nd Opinion From Johns Hopkins

I will try to be as concise as possible. I just turned 70. In December of last year my primary care...
Abraxis49 profile image

Are teeth affected by ADT or Xtandi?

after about 2 months of Lupron and Xtandi my teeth are tender and sore. Any correlation?

By Tim Baker. Author of Patting the Shark.

I miss my cock. The size and appearance of my old fella was nothing remarkable. Circumcised, a tad...